Fulcrum therapeutics® reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass., feb. 11, 2022 (globe newswire) -- fulcrum therapeutics, inc. (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the grant of inducement awards outside of the company's 2019 stock incentive plan to amy winnen, the company's newly appointed vice president, head of market value, access and policy. the grant was approved by a majority of the independent directors of the company on february 3, 2022 as an inducement material to the employee entering into employment with the company in accordance with nasdaq listing rule 5635(c)(4).
FULC Ratings Summary
FULC Quant Ranking